Figure 1. Vector map and studies in normal mice on standard diets.

(A) AAV8.UCn2 map. Initial studies in mice determined that AAV8.CBA.UCn2 is the optimal AAV serotype and promoter for the proposed studies resulting in a sustained increase in plasma UCn2 levels over 7 months (5). (B) Fasting glucose. Normal mice received i.v. AAV8.UCn2 (5 × 10¹¹ gc, n = 8), saline (CON, n = 8), or AAV9.EGFP (5 × 10¹¹ gc, n = 4) and standard chow for 3 weeks. A 24% reduction in fasting glucose was seen after AAV8.UCn2 gene transfer (P = 0.01). (C) AAV8.UCn2 dose-glucose response relationship. AAV8.UCn2 doses of 5 × 10⁹ to 5 × 10¹¹ gc produced 21%–33% reduction in fasting glucose levels in normal mice. We selected the highest dose (5 × 10¹¹ gc) for studies conducted in insulin resistant mice. In all graphs, data are mean ±SEM; P values are from Student’s t test for unpaired data, 2 tails, unless stated otherwise.